Literature DB >> 4077288

Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations.

T A Golper, S K Wedel, A A Kaplan, A M Saad, S T Donta, E P Paganini.   

Abstract

We have discussed the basic principles of pharmacokinetics and convective solute removal in the context of each other. Clinical observations appear to follow the theoretical expectations. For practical purposes plasma and plasma water are not different. In the calculation of drug sieving, venous samples do not contribute enough to warrant their extra costs. We recommend that drug removal in hemofiltration be expressed by the sieving coefficient, UF/A. Drug sieving data in humans undergoing CAVH are tabulated. Recommendations for supplemental dosing are discussed which are applicable to any clinical setting.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4077288

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN： 0391-3988            Impact factor:   1.595


  12 in total

Review 1.  Drug removal by continuous arteriovenous haemofiltration. A review of the evidence in poisoned patients.

Authors:  T A Golper; W M Bennett
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

2.  Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing.

Authors:  Catherine S C Bouman; Hendrikus J M van Kan; Richard P Koopmans; Johanna C Korevaar; Marcus J Schultz; Margreeth B Vroom
Journal:  Intensive Care Med       Date:  2006-10-17       Impact factor: 17.440

3.  Pharmacokinetics of ranitidine in patients undergoing haemofiltration.

Authors:  U Gladziwa; D R Krishna; U Klotz; T H Ittel; H Schunkert; W M Glöckner; H Mann
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.

Authors:  Eric Wenzler; Kristen L Bunnell; Susan C Bleasdale; Scott Benken; Larry H Danziger; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  Clinical use of ganciclovir during renal failure and continuous hemodialysis.

Authors:  O Bastien; R Boulieu; N Bleyzac; S Estanove
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

Review 6.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 7.  Clinical pharmacokinetics during continuous haemofiltration.

Authors:  F Bressolle; J M Kinowski; J E de la Coussaye; N Wynn; J J Eledjam; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

8.  Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy.

Authors:  M Biagi; D Butler; X Tan; S Qasmieh; K Tejani; S Patel; R M Rivosecchi; M H Nguyen; C J Clancy; R K Shields; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

Review 9.  A review of continuous renal replacement therapy.

Authors:  C G Flynn
Journal:  Ir J Med Sci       Date:  1994-07       Impact factor: 1.568

10.  Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.

Authors:  Eric Wenzler; David Butler; Xing Tan; Takayuki Katsube; Toshihiro Wajima
Journal:  Clin Pharmacokinet       Date:  2021-11-18       Impact factor: 5.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.